Literature DB >> 12233091

[Recurrence of intracranial germinoma initially treated with chemotherapy only].

Toshihiro Kumabe1, Yasuko Kusaka, Hidefumi Jokura, Hidetoshi Ikeda, Reizo Shirane, Takashi Yoshimoto.   

Abstract

Irradiation for intracranial germinoma may be associated with significant neuroendocrinological sequelae, so the establishment of lower effective doses of radiation is desirable. Eight consecutive patients with intracranial germinoma underwent combination chemotherapy with BEP (bleomycin, etoposide, and cisplatin) or PE (cisplatin and etoposide) without irradiation between 1996 and 1997. The diagnosis was based on endoscopic or stereotactic biopsy, or transsphenoidal surgery in 7 cases. These 7 patients obtained complete response (CR) after treatment with chemotherapy only. The diagnosis of pure germinoma was based on neuroradiographic appearances and the normal levels of tumor markers in patients with suprasellar and pineal-region germ cell tumors. Although all patients obtained CR, 5 patients relapsed at a mean period of 19 months after the initial therapy. The mean follow-up period was 53 months. Two of these 5 patients had recurrence around the ventricle wall. Additional chemotherapy and total ventricle irradiation (24 Gy) achieved CR, but delayed seeding in the optic nerves outside the irradiated field was detected. One patient suffered peritoneal dissemination via a ventriculoperitoneal shunt with intracranial dissemination. Another patient obtained CR after PE therapy, but there was not histological verification. However, 35 months after the initial therapy, surgical extirpation of the recurrent tumor revealed immature teratoma. One patient refused treatment for recurrence at the initial tumor site and died 42 months after the initial treatment. Adequate initial therapy is absolutely essential for the treatment of intracranial germinoma. The chemotherapy regimens in use today cannot be recommended as initial therapy without irradiation because of the high recurrence rates.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12233091

Source DB:  PubMed          Journal:  No Shinkei Geka        ISSN: 0301-2603


  7 in total

Review 1.  Recent advances in molecular biology and treatment strategies for intracranial germ cell tumors.

Authors:  Xiang Huang; Rong Zhang; Ying Mao; Liang-Fu Zhou; Chao Zhang
Journal:  World J Pediatr       Date:  2016-06-29       Impact factor: 2.764

2.  Combined chemotherapy and radiotherapy for intracranial germinomas in adult patients: a single-institution study.

Authors:  Antonio Silvani; Marica Eoli; Andrea Salmaggi; Elena Lamperti; Laura Fariselli; Ida Milanesi; Giovanni Broggi; Carlo Lazzaro Solero; Sergio Giombini; Amerigo Boiardi
Journal:  J Neurooncol       Date:  2005-02       Impact factor: 4.130

3.  Rapidly growing giant suprasellar tumor in a high-risk child: treatment strategy and role of neuroendoscopic surgery in slit-like ventricles.

Authors:  Saad Hamdan Abdullah; Koreaki Irie; Shizuo Oi
Journal:  Childs Nerv Syst       Date:  2005-06-17       Impact factor: 1.475

4.  Treatment strategy for intracranial primary pure germinoma.

Authors:  Kyu-Won Shim; Eun Kyung Park; Yoon-Ho Lee; Chang-Ok Suh; Jaeho Cho; Joong-Uhn Choi; Dong-Seok Kim
Journal:  Childs Nerv Syst       Date:  2012-09-11       Impact factor: 1.475

5.  Treatment failure in intracranial primary germinomas.

Authors:  Kyu-Won Shim; Tae-Gon Kim; Chang-Ok Suh; Jae-Ho Cho; Chul-Joo Yoo; Joong-Uhn Choi; Jung-Hee Kim; Dong-Seok Kim
Journal:  Childs Nerv Syst       Date:  2007-07-04       Impact factor: 1.475

6.  Indications for salvage surgery during treatment for intracranial germ cell tumors.

Authors:  Masayuki Kanamori; Toshihiro Kumabe; Mika Watanabe; Masashi Chonan; Ryuta Saito; Yoji Yamashita; Yoshikazu Ogawa; Yukihiko Sonoda; Teiji Tominaga
Journal:  J Neurooncol       Date:  2018-03-26       Impact factor: 4.130

7.  Germinoma involving the basal ganglia in children.

Authors:  Tai-Tong Wong; Y W Chen; Wan-Yuo Guo; Kai-Ping Chang; Donald M Ho; Sang-Hue Yen
Journal:  Childs Nerv Syst       Date:  2007-09-29       Impact factor: 1.475

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.